Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.
Schneider TC, de Wit D, Links TP, van Erp NP, van der Hoeven JJ, Gelderblom H, Roozen IC, Bos M, Corver WE, van Wezel T, Smit JW, Morreau H, Guchelaar HJ, Kapiteijn E. Schneider TC, et al. Among authors: van erp np, van wezel t, van der hoeven jj. J Clin Endocrinol Metab. 2017 Feb 1;102(2):698-707. doi: 10.1210/jc.2016-2525. J Clin Endocrinol Metab. 2017. PMID: 27870581 Clinical Trial.
Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer.
de Wit D, Schneider TC, Moes DJ, Roozen CF, den Hartigh J, Gelderblom H, Guchelaar HJ, van der Hoeven JJ, Links TP, Kapiteijn E, van Erp NP. de Wit D, et al. Among authors: van erp np, van der hoeven jj. Cancer Chemother Pharmacol. 2016 Jul;78(1):63-71. doi: 10.1007/s00280-016-3050-6. Epub 2016 May 11. Cancer Chemother Pharmacol. 2016. PMID: 27169792 Free PMC article. Clinical Trial.
Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial.
Schneider TC, de Wit D, Links TP, van Erp NP, van der Hoeven JJ, Gelderblom H, van Wezel T, van Eijk R, Morreau H, Guchelaar HJ, Kapiteijn E. Schneider TC, et al. Among authors: van eijk r, van erp np, van wezel t, van der hoeven jj. Int J Endocrinol. 2015;2015:348124. doi: 10.1155/2015/348124. Epub 2015 Jul 29. Int J Endocrinol. 2015. PMID: 26294908 Free PMC article.
Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry.
van Zeijl MCT, de Wreede LC, van den Eertwegh AJM, Wouters MWJM, Jochems A, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van der Hoeven JJM, Haanen JBAG. van Zeijl MCT, et al. Eur J Cancer. 2021 Feb;144:242-251. doi: 10.1016/j.ejca.2020.11.028. Epub 2020 Dec 26. Eur J Cancer. 2021. PMID: 33373869
Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice.
Samsom KG, Bosch LJW, Schipper LJ, Schout D, Roepman P, Boelens MC, Lalezari F, Klompenhouwer EG, de Langen AJ, Buffart TE, van Linder BMH, van Deventer K, van den Burg K, Unmehopa U, Rosenberg EH, Koster R, Hogervorst FBL, van den Berg JG, Riethorst I, Schoenmaker L, van Beek D, de Bruijn E, van der Hoeven JJM, van Snellenberg H, van der Kolk LE, Cuppen E, Voest EE, Meijer GA, Monkhorst K. Samsom KG, et al. Among authors: van der hoeven jjm. Nat Protoc. 2024 Mar;19(3):700-726. doi: 10.1038/s41596-023-00933-5. Epub 2023 Dec 13. Nat Protoc. 2024. PMID: 38092944 Review.
Practice variation in re-resection for recurrent glioblastoma: A nationwide survey among Dutch neuro-oncology specialists.
van Opijnen MP, de Vos FYF, Nabuurs RJA, Snijders TJ, Nandoe Tewarie RDS, Taal W, Verhoeff JJC, van der Hoeven JJM, Broekman MLD. van Opijnen MP, et al. Among authors: van der hoeven jjm. Neurooncol Pract. 2023 Mar 14;10(4):360-369. doi: 10.1093/nop/npad016. eCollection 2023 Aug. Neurooncol Pract. 2023. PMID: 37457228 Free PMC article.
91 results